Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Individualized Cancer Therapy (iCAT) Recommendation for Patients With Recurrent, Refractory or High Risk Solid Tumors

NCT01853345 is registered in ClinicalTrials.gov with Dana-Farber Cancer Institute as lead sponsor.

NCT NCT01853345
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01853345 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Individualized Cancer Therapy (iCAT) Recommendation for Patients With Recurrent, Refractory or High Risk Solid Tumors
Lead sponsor
Dana-Farber Cancer Institute
Phase
Observational
Overall status
Completed
Start date
August 31, 2012
Completion date
Not reported
Enrollment
101 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

neuroblastoma, pediatric solid tumor, sarcoma, wilms tumor